|Bid||3.08 x 3000|
|Ask||3.09 x 1000|
|Day's Range||3.02 - 3.35|
|52 Week Range||1.60 - 8.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 9, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.44|
Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today reported positive and sustained six-month data from an ongoing single-arm feasibility study using its cryogen-cooled, monopolar radiofrequency (CMRF) technology platform for the treatment of mild-to-moderate stress urinary incontinence (SUI) in women. The ongoing study is being conducted by Bruce Allan, PhD, MD, FRCS(C), founder and medical director of the Allan Centre in Calgary, Alberta. “These new data are extremely encouraging for women suffering from stress urinary incontinence, further validating the positive 12-month SUI pilot study data that we reported in February.
Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that is has reached a settlement to resolve the patent litigation that it filed in 2016 against ThermiGen, LLC, ThermiAesthetics, LLC, and Dr. Red Alinsod in the U.S. District Court for the Eastern District of Texas citing infringement of Viveve’s intellectual property (Viveve, Inc. v. ThermiGen, LLC, No.2:16-1189). Under the settlement, Viveve will receive a monetary payment and on-going royalty, as well as other mutual agreements relating to certain intellectual property owned by the companies.
Viveve Medical, Inc. is a women's intimate health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System, that delivers the Viveve treatment, incorporates clinically-proven cryogen-cooled, monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate robust neocollagenesis in a single 30-minute in-office session.
Viveve (VIVE) reported Q1 2018 financial results and provided a business update. Despite what we’d characterize as a pretty disappointing start to the year, management reiterated their previously issued 2018 revenue guidance in the range of $22M (+44%) to $24M (+57%). VIVE indicated that realignment of the sales force/territories and a national sales meeting (which sidelined the entire sales force for a week) significantly impacted Q1 domestic sales results.
Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that patient enrollment is underway in the multicenter randomized VIveve Treatment of the Vaginal Introitus to EValuate Safety and Efficacy (VIVEVE II) clinical study to assess the safety and effectiveness of the Viveve® System for the improvement of sexual function in women following vaginal childbirth. As a result, we anticipate submitting the 30-day safety data from the first 25 treated patients to the FDA for review by the end of the second quarter,” said Scott Durbin, chief executive officer of Viveve.
Continued quarter-over-quarter annual revenue growth and rapid expansion into stress urinary incontinence market planned for Viveve ® System. ENGLEWOOD, Colo., May 10, 2018-- Viveve Medical Inc., a medical ...
Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin has been appointed as the company’s Chief Executive Officer, effective immediately. Mr. Durbin, a seasoned healthcare executive and the company’s former Chief Financial Officer, will also join the Board of Directors. Mr. Durbin’s appointment follows Patricia Scheller’s decision to step down from her position as Chief Executive Officer to pursue other personal and business opportunities.
Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced it will report financial results for the first quarter ended March 31, 2018 on Thursday, May 10, 2018 after the close of the U.S. financial markets. The company will also host a live conference call and webcast to discuss these financial results and provide an update on corporate and commercial developments. Participating on the call will be Patricia Scheller, chief executive officer and director, Scott Durbin, chief financial officer, and James Atkinson, chief business officer and president.
The business update encompassed several near-term goals including further significant growth of the direct sales force, regulatory approval and entry into additional territories, progress towards label expansion, introduction of complementary products and continued strong revenue and margin growth. Just days after the Q4 earnings announcement, VIVE received notice that FDA approved their IDE to conduct ‘VIVEVE II’, the clinical trial which is expected to serve as primary support for an eventual U.S. regulatory filing seeking clearance for a ‘sexual-function’ related indication. While very long-in-the-tooth, the IDE approval was welcome news as it means that Geneveve could relatively soon be the only energy-based technology cleared by FDA for such an indication.
|Initiated||Stifel Nicolaus: to Buy||4/17/2018|
|Initiated||Empire Asset Management: to Buy||2/22/2018|
|Initiated||Northland Securities: to Outperform||1/5/2018|
|Initiated||Mizuho: to Buy||11/17/2017|
|Initiated||Raymond James: to Outperform||5/25/2017|
|Initiated||Cowen & Co.: to Outperform||5/3/2017|
Industry: Medical Devices
Full Time Employees: 103
Viveve Medical, Inc. designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories. It markets its products through sales employees and distributors in the United States, the Asia Pacific, Europe, the Middle East, Latin America, and Canada. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.